- Login
- Register & Subscribe
- Sprache: EN FR DE
Company News
Zealand Pharma announces departure of CSO
Friday 15 March 2013
Zealand Pharma A/S of Denmark has announced the departure of its chief scientific officer, Christian Grøndahl, who is leaving the company to pursue other interests. Dr Grøndahl joined the company in 2010 and was appointed CSO on 3 January 2011.
Location
Denmark
Mesoblast raises A$170 million for cell therapies
Thursday 14 March 2013
Mesoblast Ltd of Australia has raised A$170 million (€136.3 million) in a private placement of its shares with existing and new investors including M&G Investment Management and Capital Research. The monies will fund the company’s cell therapies.
Location
Australia
Shire acquires Premacure of Sweden
Wednesday 13 March 2013
Shire Plc has expanded its portfolio of potential medicines for rare diseases with the acquisition of the privately-held Swedish company, Premacure AB, of Uppsala. The key asset is a protein replacement therapy for the prevention of retinopathy of prematurity.
Location
United States
4SC shareholders summoned to discuss loss
Wednesday 13 March 2013
Auditors for Germany’s 4SC AG have declared that the company has cash to support its activities into the third quarter of 2014. Nevertheless shareholders will be told at an upcoming meeting that losses now amount to half of the company’s share capital.
Location
Germany
Record revenue for Galápagos in 2012
Saturday 9 March 2013
Milestone payments from partners and a strong performance of its service business boosted revenue at Galápagos NV in 2012 and dramatically reduced its loss for the year. Cash on 31 December was €94.7 million.
Location
Belgium
Cell Medica expands management team
Saturday 9 March 2013
Just eight months after securing £17 million in new equity, Cell Medica Ltd has expanded its management team to appoint a chief medical officer, a chief financial officer and a vice president of development all of whom will be based in the US.
Location
United Kingdom
UK start-up to advance AD compound
Friday 8 March 2013
A new UK start-up based on technology from King’s College London has received funding from Advent Venture Partners. CoCo Therapeutics Ltd will progress an approach for Alzheimer’s disease that involves the retinoic acid receptor, RAR-alpha.
Location
United Kingdom
Electrical Geodesics to list on AIM
Friday 8 March 2013
A US medical technology company, Electrical Geodesics Inc (EGI), has announced plans to raise funds and seek admission to the London Stock Exchange’s Alternative Investment Market. EGI is based in Eugene, Oregon.
Location
United Kingdom
4SC AG chief executive steps down
Thursday 7 March 2013
Ulrich Dauer, a co-founder and the current chief executive and chair of the management board of 4SC AG, will be stepping down from his positions effective 31 March. Announcing the move on 6 March, the German company cited “personal reasons.”
Location
Germany
MorphoSys to raise R&D spending
Wednesday 6 March 2013
MorphoSys AG expects to increase spending on its proprietary antibody programmes this year after a reduction in investment in 2012 in order to push forward an in-licensed compound for cancer. It is also in active discussions to partner its antibody for RA.
Location
Germany
Select a News Category
Recent Appointments
Pascale Witz to head strategic development at Sanofi
Monday May 6 2013
Srinivas Akkaraju joins Sofinnova Ventures
Monday May 6 2013
Vicente Anido nominated to Nicox board
Monday May 6 2013
Jeremy Farrar named director of the Wellcome Trust
Monday May 6 2013
Harry Kirsch becomes CFO at Novartis
Monday May 6 2013